08:25:37 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Ordinarie utdelning GTAB B 0.00 SEK
2024-05-29 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-02-28 Bokslutskommuniké 2023
2023-11-29 Kvartalsrapport 2023-Q3
2023-11-16 Extra Bolagsstämma 2023
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-31 Ordinarie utdelning GTAB B 0.00 SEK
2023-05-30 Årsstämma 2023
2023-05-24 Kvartalsrapport 2023-Q1
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-06-01 Ordinarie utdelning GTAB B 0.00 SEK
2022-05-31 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-09 Ordinarie utdelning GTAB B 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning GTAB B 0.00 SEK
2020-06-11 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1
2020-02-21 Bokslutskommuniké 2019
2019-11-27 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning GTAB B 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-21 Kvartalsrapport 2018-Q3
2018-08-29 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning GTAB B 0.00 SEK
2018-05-30 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-29 Kvartalsrapport 2017-Q2
2017-06-02 Ordinarie utdelning GTAB B 0.00 SEK
2017-06-01 Årsstämma 2017
2017-05-23 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-06-10 Ordinarie utdelning GTAB B 0.00 SEK
2016-06-09 Årsstämma 2016
2016-05-20 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-06-10 Ordinarie utdelning GTAB B 0.00 SEK
2015-06-09 Årsstämma 2015
2015-05-22 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-06-06 Ordinarie utdelning GTAB B 0.00 SEK
2014-06-05 Årsstämma 2014
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-06 Bokslutskommuniké 2013
2013-11-22 Kvartalsrapport 2013-Q3
2013-08-23 Kvartalsrapport 2013-Q2
2013-05-31 Ordinarie utdelning GTAB B 0.00 SEK
2013-05-30 Årsstämma 2013
2013-05-15 Kvartalsrapport 2013-Q1
2013-02-07 Bokslutskommuniké 2012
2012-11-01 Kvartalsrapport 2012-Q3
2012-09-28 Kapitalmarknadsdag 2012
2012-08-22 Kvartalsrapport 2012-Q2
2012-06-15 Ordinarie utdelning GTAB B 0.00 SEK
2012-06-14 Årsstämma 2012
2012-05-10 Kvartalsrapport 2012-Q1
2012-02-08 Bokslutskommuniké 2011
2011-11-01 Kvartalsrapport 2011-Q3
2011-08-23 Kvartalsrapport 2011-Q2
2011-06-15 Ordinarie utdelning GTAB B 0.00 SEK
2011-06-14 Årsstämma 2011
2011-04-27 Kvartalsrapport 2011-Q1
2011-01-26 Bokslutskommuniké 2010
2010-10-29 Kvartalsrapport 2010-Q3
2010-08-20 Kvartalsrapport 2010-Q2
2010-06-09 Ordinarie utdelning GTAB B 0.00 SEK
2010-06-08 Årsstämma 2010
2010-04-30 Kvartalsrapport 2010-Q1
2010-02-05 Bokslutskommuniké 2009
2009-10-30 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaNGM
SektorHälsovård
IndustriLäkemedel & Handel
Glycorex Transplantation är verksamt inom bioteknik. Bolaget bedriver forskning, utveckling och marknadsföring inom området för organtransplantation. Bolagets huvudprodukt Glycosorb-ABO möjliggör transplantationer oavsett blodgrupp hos givare respektive mottagare. Transplantation med hjälp utav bolagets produkt utförs på global nivå. Glycorex Transplantation grundades år 1996 och har sitt huvudkontor i Lund.
2023-02-20 12:00:00

In February 2022 the transplant team at the Groote Schuur Hospital in Cape Town, South Africa, as the first hospital on the African continent, performed a blood group incompatible kidney transplant using Glycosorb® ABO on a patient who had been on the transplant waiting list for almost 10 years. "The Groote Schuur Hospital transplant team are excited to be able to bring this technology to our patients, allowing more patients access to transplantation," said Dr Zunaid Barday, Nephrologist at Groote Schuur Hospital.

As with most patients needing a kidney transplant, the journey for this patient has not been easy. In December 2013, she was admitted to hospital where she was due to give birth to her third child. At this same time her kidneys failed. She was immediately transferred to Groote Schuur Hospital for treatment. She was placed on a renal dialysis treatment program and has been on dialysis since then. A procedure to remove waste products and excess fluid from the blood when the kidneys stop working properly.

The patient has been on the kidney transplant waiting list since then, as she had no blood group compatible donors and she is blood group O, for which the waiting list has gotten longer over the years, and COVID exacerbated this even more. With the Glycosorb® ABO medical device a blood group incompatible kidney transplant from a living donor was possible. "I was so overwhelmed as this was not an easy journey and so I am grateful that I could have the transplant. I can now live a normal life and provide for my children," the patient said after the transplantation.

"The Groote Schuur Hospital transplant team are excited to be able to bring this technology to our patients, allowing more patients access to transplantation, and continuing our proud legacy of innovation in transplantation. With this technology, we can now safely transplant many patients across incompatible blood groups, which was an absolute barrier previously. This will allow potential living kidney donors who were turned down previously because they were the wrong blood group for the person they wanted to donate to, to come forward again to be retested. This should result in more patients who have been on the transplant waiting list, sometimes for many years, to get a successful kidney transplant," said Dr Zunaid Barday, Nephrologist at Groote Schuur Hospital.

"We at Glycorex, together with our South African distributor partner Coligo Medical, are grateful to have been able to support Dr Barday and the Groote Schuur Hospital Renal Transplant Unit in successfully performing the first blood group incompatible kidney transplant with our medical device Glycosorb® ABO in South Africa. We are dedicated to continuing the collaboration with health care professionals around the world to enable more patients to undergo a life changing transplantation," said Johan Lavén, CEO at Glycorex Transplantation AB.